 |
|
|
|
|
|
|
|
|
|
|
|
1 to 7 of 7 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Carare R, Hawkes C, Weller R. on NEWS: ApoE4 Makes Blood Vessels Leak, Could Kick Off Brain Damage, This paper represents a natural progression for the group that has clarified the effect of... 17 May 2012.
|
|
|
 |
|
|
Boche D, Carare R, Hawkes C, Nicoll J, Weller R. on NEWS: Australia Report: Aβ Toxicity, ApoE, Failure of Perivascular Drainage of Aβ With Age and Its Relevance for Alzheimer's... 21 Oct 2011.
|
|
|
|
|
|
Carare R, Hawkes C. on NEWS: ApoA1: Does Good Cholesterol Protect the Brain?, There is now substantial evidence that the accumulation of soluble and insoluble amyloid beta... 5 Oct 2010.
|
|
|
|
|
|
Carare R, Weller R. on PAPER: Bugiani O. et al., 2010, This paper by Bugiani et al., is a clearly written and beautifully illustrated account of the... 13 Aug 2010.
|
|
|
|
|
|
Carare R, Weller R. on PAPER: Schroeter S. et al., 2008, Prevention Rather Than Cure of CAA May Be the Best Way Forward
Increased severity of... 15 Jul 2008.
|
|
|
|
|
|
Carare R, Weller R. on NEWS: Trial Troika—Immunotherapy Interrupted, Lipitor Lags, Dimebon Delivers, Aβ Immunotherapy Trial Interrupted by Suspected Vasculitis in the Skin
Alzforum... 19 May 2008.
|
|
|
|
|
|
Carare R, Weller R. on SITE POLL: What is the most likely mechanism by which aging contributes to AD pathogenesis?, Comment by Roy O. Weller, Roxana Carare-Nnadi, and James A.R.... 2 May 2004.
|
|
|
|
|
|
|
1 to 7 of 7 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
